05 Compliance

Where alkaline protease is permitted, and what the file must show

Technical document 05 · Reviewed 2026-11-19 · Alkaline Protease

On this page
  1. Four questions, four answers
  2. European Union: national rules while the list is pending
  3. United States: the route depends on the organism
  4. United Kingdom: GB and Northern Ireland separately
  5. Limits and where they come from
  6. The claim is the brand’s document
  7. What ships with the lot
  8. Checks before release to a market

Alkaline protease is regulated as a food enzyme preparation rather than as a nutrient, so permission attaches to the preparation — production organism, strain, fermentation inputs and carrier — and to the market where it is sold. In the European Union the Union list is still pending and national provisions govern placing on the market; in the United States the route depends on the production organism; in the United Kingdom the assimilated regulation applies, with a separate position for Northern Ireland. Use, purity, labelling and claims are four separate questions, and the file has to answer each one.

In one line

Permission attaches to the preparation and the market, so the file has to name the organism, the strain, the carrier and the use — the activity figure does not carry the authorisation.

Four questions, four answers

The first question is permitted use: may this preparation be used in the intended food process in this market? The second is purity: does the lot stay inside the contaminant and microbiological limits? The third is description: how is the preparation named on the label, including its carrier? The fourth is claims: what may the brand say about the finished product?

“Alkaline protease” is an activity class, not one authorised substance. The enzyme is a subtilisin-type serine endopeptidase, EC 3.4.21.62, with CAS 9014-01-1, and the preparation from Bacillus licheniformis is what a dossier describes. Two powders can both read 200,000 U/g and sit under different regulatory positions, which is why the file names the organism and the strain.

European Union: national rules while the list is pending

Regulation (EC) No 1332/2008 is the framework. It makes entry on the Union list a condition of marketing and food use, and that list is still outstanding as of this review. The transitional position leaves national provisions on placing on the market and use in force in the Member States, so the file should name the Member State of sale rather than “the EU”.

Applications sit on a Commission register, and the file should identify the entry for this enzyme and this use. EFSA assesses the production strain and the process, not the activity name in the abstract, so the evidence is tied to the organism and the fermentation. “EU approved” is not an accurate description while the list is pending; the defensible wording names the national provision, the register entry and the application status. Check the current text before launch.

For a supplement, Directive 2002/46/EC and the national implementing rules apply in parallel, and Regulation (EU) No 1169/2011 governs the ingredient list. An enzyme with a technological function in the finished product is declared as an ingredient; one that acts only during processing is a processing aid.

United States: the route depends on the organism

The food-enzyme regulation that is usually cited, 21 CFR 184.1150, describes a bacterially derived protease preparation from Bacillus subtilis or Bacillus amyloliquefaciens, containing subtilisin and neutral proteinase, affirmed as GRAS for protein hydrolysis under current good manufacturing practice and requiring the absence of antibiotic activity by a validated method.

A preparation from Bacillus licheniformis is a different organism, so that citation alone does not describe it. The usual basis is a GRAS notice specific to the organism, the strain and the preparation, or a self-affirmed GRAS file held by the manufacturer; check the FDA inventory for the current listing and the intended use. For a dietary supplement the brand also needs a dietary-ingredient basis under DSHEA and cGMP under 21 CFR 111, and the label follows 21 CFR 101.36, where enzyme activity is a specification rather than a nutrient with a daily value.

United Kingdom: GB and Northern Ireland separately

In Great Britain the assimilated version of Regulation (EC) No 1332/2008 applies, with authorisations held on the register maintained by the Food Standards Agency and Food Standards Scotland. The position should be checked for the specific enzyme, strain and use. Northern Ireland follows the EU regime, so a GB check does not answer the NI question.

Limits and where they come from

Contaminant and microbiological limits · catalog and EU food-supplement ceilings
ParameterCatalog limitMarket note
Lead≤3 mg/kgEU supplements: 3.0 mg/kg on the product as sold
Arsenic≤2 mg/kgNo general EU limit for this matrix; the catalog sets 2 mg/kg
Cadmium≤1 mg/kgEU supplements: 1.0 mg/kg as sold
Mercury≤0.1 mg/kgEU supplements: 0.10 mg/kg as sold
MicrobiologyAPC ≤10,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absentGeneral food-safety obligation; customer limits can be stricter
Loss on drying≤8.0%Quality parameter; it also sets the activity basis

Regulation (EU) 2023/915 sets the EU ceilings on the supplement as sold, not on the enzyme powder. The ingredient limit has to be chosen so that the finished product stays below the ceiling, and that calculation belongs to the brand; the certificate is one input. US state rules and UK requirements can be tighter than the catalog, so the destination limit is checked.

The claim is the brand’s document

This material carries no disease-related claim, and these pages cover the specification and the file rather than any effect in the body. “Alkaline protease activity ≥200,000 U/g” is a specification statement, not a health claim, and it belongs on the technical data sheet.

Anything said about the finished product belongs to the brand and must satisfy the rules of the market where it is sold: the EU health-claims regulation, the US supplement framework and the retained UK regime each apply their own test. The enzyme file can support identity, activity and purity; it cannot support a statement about what the finished product does.

What ships with the lot

  • Specification naming the unit, the assay method and the activity basis.
  • Lot certificate with result and limit in separate columns.
  • Technical data sheet covering activity, solubility, pH and pack format.
  • Safety data sheet with the dust-control and exposure sections; enzyme powders are respiratory sensitisers.
  • Allergen declaration: source organism and carrier.
  • Statement on GMO status for the organism and its inputs.
  • Origin record and strain declaration.
  • Composition statement, including the carrier.
  • Stability summary, grade- and pack-specific.
  • Residual-solvent statement for the recovery process.

Checks before release to a market

Market release checks for an alkaline protease lot
CheckEvidence
Market and process namedMemo covering the intended use, not only the substance
Organism and strain recordedOrigin file and strain declaration
Regulatory status confirmedEU register entry or national provision, a US GRAS basis for the organism, or the UK register position
Contaminants inside the destination limitLot COA, plus a third-party report where needed
Carrier and allergen checkedComposition statement and label artwork
Pack wording checkedActivity, unit, carrier and storage on the label
Claims reviewedSubstantiation file held by the brand
Document pack completeThe ten items above, matched to the lot

The catalog entry is on the alkaline protease product page; the release lines are on the COA page; the source and activity evidence is on the identity page; and the frameworks are summarised in the EU, US and UK notes. The quality page describes the release workflow.

Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.

Request a quotation